Resources Repository
-
ArticlePublication 2018Comparing Cost-per-QALYs Gained to Cost-per-DALYs Averted
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, …
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, the Tufts Medical Center CEA Registry (cost-per-QALY gained studies), and the Global Cost-Effectiveness Analysis (GHCEA) Registry (cost-per-DALY averted studies). Study characteristics that were analyzed included intervention type, sponsor, country, primary disease, and number of CEAs versus disease burden estimates for major conditions. The authors report that cost-per-QALY studies were most often about pharmaceuticals or interventions in high-income countries while cost-per-DALY…
Cost-Effectiveness Analysis | Evidence Synthesis | Policy/Regulation | Health/Medicine | Global -
ArticlePublication 2018Cost-Effectiveness of Strategies to Prevent Road Traffic Injuries in Eastern Sub-Saharan Africa and Southeast Asia: New Results from WHO-CHOICE
The authors applied a generalized cost-effectiveness analysis (GCEA) approach, applying a null reference case, in …
The authors applied a generalized cost-effectiveness analysis (GCEA) approach, applying a null reference case, in which the effects of currently implemented interventions were subtracted from current rates of burden, in order to identify the most efficient package of interventions that could be applied to Road Traffic Injuries (RTIs). They used a population model to estimate costs and effectiveness of interventions over a 100 year time frame in eastern sub-Saharan Africa and Southeast Asia. All heath…
Cost-Effectiveness Analysis | State-Transition | Injuries/Accidents | Policy/Regulation | Culture/Society | Science/Technology | Sub-Saharan Africa | Asia & Pacific -
ReviewPublication 2018Equity Considerations in CEA: Rotavirus Vaccine in LMIC's
The authors used a systematic review of the literature to identify economic evaluations of rotavirus …
The authors used a systematic review of the literature to identify economic evaluations of rotavirus vaccine in LMICs and assess the extent to which equity was considered in the objectives, analysis, and results. They used equity-related indicators provided in the Guidance on Priority Setting in Health Care (GPS-Health) checklist criteria resulting in 18 unique indicators tracked. The authors found that some articles incorporated the indicators in their model inputs (20%) while the majority (80%) presented…
Cost-Effectiveness Analysis | Evidence Synthesis | Infectious Diseases | Social Determinants | Health/Medicine | Global -
ArticlePublication 2018HTA and MCDA Solely or Combined? The Case of Priority-Setting in Colombia
Given the limited resources available worldwide, healthcare systems face problems of justice and efficiency related …
Given the limited resources available worldwide, healthcare systems face problems of justice and efficiency related to setting priorities. Two methods, Health Technology Assessment (HTA) and Multi-Criteria Decision Analysis (MCDA) have emerged as tools to assist in informed decision-making, but both have advantages and disadvantages. Colombia established a Health Technology Assessment Institute in 2012. The authors discuss challenges faced by the Colombian health system, characteristics of HTA in Colombia and the potential benefits and drawbacks of…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Health Systems | Policy/Regulation | Health/Medicine | Latin America & Caribbean -
ArticlePublication 2018Resource Allocation in Decision Support Frameworks
Multi-criteria decision-making frameworks expand on typical decision analyses (cost-effectiveness and cost-benefit) by explicitly incorporating value …
Multi-criteria decision-making frameworks expand on typical decision analyses (cost-effectiveness and cost-benefit) by explicitly incorporating value tradeoffs from decision makers and summarizing the performance of investment options. This is done across all chosen dimensions of value, based on the weights provided by the decision makers, but comes at a cost. Currently there is no widely accepted method to suggest how to determine a budget constraint using multi-attribute models or to measure willingness to pay for incremental…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Benefit-Cost Analysis | Health Systems | Health/Medicine | Global -
ArticlePublication 2018Should We Treat Acute Hepatitis C? A Decision and Cost-Effectiveness Analysis
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared …
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared to deferring treatment until the chronic phase, utilizing a microsimulation model. By projecting long-term outcomes such as quality-adjusted life years (QALYs) and costs, the analysis evaluates the cost-effectiveness of initiating therapy during the acute phase. Results indicate that treating acute HCV increases QALYs by 0.02 and costs by $483 per patient not at risk of transmitting HCV, yielding an incremental…
Cost-Effectiveness Analysis | Microsimulation | Decision Analysis | Infectious Diseases | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2018Equity Impact Vaccines May Have on Averting Deaths and Medical Impoverishment
In this analysis, authors estimated the number of deaths averted and the number of cases …
In this analysis, authors estimated the number of deaths averted and the number of cases of medical impoverishment averted of ten antigens and their corresponding vaccines across income quintiles for forty-one low- and middle-income countries. The study found that vaccines administered between 2016 and 2030 would prevent 36 million deaths. Vaccines will have the greatest impact on reducing cases of poverty caused by hepatitis B, helping an estimated 14 million people avoid medical impoverishment. An…
Cost-Effectiveness Analysis | Priority Setting/Ethics | Costing Methods | Health Outcomes | Mathematical Models | Infectious Diseases | Child/Nutrition | Global Governance | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2018DALYS and QALYs – Does the Choice of Measure Matter?
This article discusses the measurement of health benefits as a key issue in health economic …
This article discusses the measurement of health benefits as a key issue in health economic evaluations. Authors adapted two previously published models, a Markov model for human papilloma virus (HPV) vaccination, and a pneumococcal vaccination deterministic model (PNEUMO) that reported outputs in QALYs to estimate DALYs in 3 settings, Argentina, Chile, and the United Kingdom. While the authors found that QALY gains were larger than DALYs avoided in all countries for HPV, differences using QALYs…
Cost-Effectiveness Analysis | Infectious Diseases | Policy/Regulation | Health/Medicine | Latin America & Caribbean | Europe -
ReviewPublication 2018Patient Variability Seldom Assessed in Cost-Effectiveness Studies
This article in Medical Decision Making reviews 200 articles published in 2014 to determine whether …
This article in Medical Decision Making reviews 200 articles published in 2014 to determine whether each cost-effectiveness analysis (CEA) study reported subgroup results and collected data on the defining characteristics of these subgroups. Since estimates can vary across patient subgroups when characteristics are influenced by preferences, outcome risks, treatment effectiveness, life expectancy, or associated costs it can be important to track and report these differences. The authors identified whether any of the CEA subgroup results…
Cost-Effectiveness Analysis | Preferences/Values | Social Determinants | Health Systems | Policy/Regulation | Health/Medicine | Global